TECENTRIQ® (Atezolizumab)

The FDA on May 18, 2020, approved TECENTRIQ® for the first-line treatment of adult patients with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained 50% or more of tumor cells [TC 50% or more] or PD-L1 stained Tumor-Infiltrating Immune Cells [IC] covering 10% or more of the tumor area [IC 10% or more]), with no EGFR or ALK genomic tumor aberrations. TECENTRIQ® is a product of Genentech Inc.